

SEQUENCE LISTING

<110> Fuji Yakuhin Kogyo Kabushiki Kaisha

<120> Monoclonal Antibody against Canine Trypsin

<130> FJ-94PCT

<140>

<141>

<150> JP 10-236609

<151> 1998-08-10

<150> JP 11-63990

<151> 1999-03-10

<160> 5

<170> PatentIn Ver. 2.0

<210> 1

<211> 247

<212> PRT

<213> Dog Pancreas

<400> 1

Met Asn Pro Leu Leu Ile Leu Ala Phe Leu Gly Ala Ala Val Ala Thr
1 5 10 15Pro Thr Asp Asp Asp Lys Ile Val Gly Gly Tyr Thr Cys Glu Glu
20 25 30Asn Ser Val Pro Tyr Gln Val Ser Leu Asn Ala Gly Tyr His Phe Cys
35 40 45Gly Gly Ser Leu Ile Ser Asp Gln Trp Val Val Ser Ala Ala His Cys
50 55 60Tyr Lys Ser Arg Ile Gln Val Arg Leu Gly Glu Tyr Asn Ile Asp Val
65 70 75 80Leu Glu Gly Asn Glu Gln Phe Ile Asn Ser Ala Lys Val Ile Arg His
85 90 95Pro Asn Tyr Asn Ser Trp Ile Leu Asp Asn Asp Ile Met Leu Ile Lys
100 105 110Leu Ser Ser Pro Ala Val Leu Asn Ala Arg Val Ala Thr Ile Ser Leu
115 120 125Pro Arg Ala Cys Ala Ala Pro Gly Thr Gln Cys Leu Ile Ser Gly Trp
130 135 140Gly Asn Thr Leu Ser Ser Gly Thr Asn Tyr Pro Glu Leu Leu Gln Cys
145 150 155 160

Leu Asp Ala Pro Ile Leu Thr Gln Ala Gln Cys Glu Ala Ser Tyr Pro

165 170 175
 Gly Gln Ile Thr Glu Asn Met Ile Cys Ala Gly Phe Leu Glu Gly Gly
 180 185 190
 Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Val Val Cys Asn Gly
 195 200 205
 Glu Leu Gln Gly Ile Val Ser Trp Gly Tyr Gly Cys Ala Gln Lys Asn
 210 215 220
 Lys Pro Gly Val Tyr Thr Lys Val Cys Asn Phe Val Asp Trp Ile Gln
 225 230 235 240
 Ser Thr Ile Ala Ala Asn Ser
 245

<210> 2
 <211> 246
 <212> PRT
 <213> Dog Pancreas

<400> 2
 Met Lys Thr Phe Ile Phe Leu Ala Leu Leu Gly Ala Thr Val Ala Phe
 1 5 10 15
 Pro Ile Asp Asp Asp Asp Lys Ile Val Gly Gly Tyr Thr Cys Ser Arg
 20 25 30
 Asn Ser Val Pro Tyr Gln Val Ser Leu Asn Ser Gly Tyr His Phe Cys
 35 40 45
 Gly Gly Ser Leu Ile Asn Ser Gln Trp Val Val Ser Ala Ala His Cys
 50 55 60
 Tyr Lys Ser Arg Ile Gln Val Arg Leu Gly Glu Tyr Asn Ile Ala Val
 65 70 75 80
 Ser Glu Gly Gly Glu Gln Phe Ile Asn Ala Ala Lys Ile Ile Arg His
 85 90 95
 Pro Arg Tyr Asn Ala Asn Thr Ile Asp Asn Asp Ile Met Leu Ile Lys
 100 105 110
 Leu Ser Ser Pro Ala Thr Leu Asn Ser Arg Val Ser Ala Ile Ala Leu
 115 120 125
 Pro Lys Ser Cys Pro Ala Ala Gly Thr Gln Cys Leu Ile Ser Gly Trp
 130 135 140
 Gly Asn Thr Gln Ser Ile Gly Gln Asn Tyr Pro Asp Val Leu Gln Cys
 145 150 155 160
 Leu Lys Ala Pro Ile Leu Ser Asp Ser Val Cys Arg Asn Ala Tyr Pro
 165 170 175
 Gly Gln Ile Ser Ser Asn Met Met Cys Leu Gly Tyr Met Glu Gly Gly
 180 185 190

Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Val Val Cys Asn Gly
 195 200 205
 Glu Leu Gln Gly Val Val Ser Trp Gly Ala Gly Cys Ala Gln Lys Gly
 210 215 220
 Lys Pro Gly Val Ser Pro Lys Val Cys Lys Tyr Val Ser Trp Ile Gln
 225 230 235 240
 Gln Thr Ile Ala Ala Asn
 245

<210> 3
 <211> 20
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Designed
 peptide to act as an immunogen

<400> 3
 Cys Leu Ile Ser Gly Trp Gly Asn Thr Gln Ser Ile Gly Gln Asn Tyr
 1 5 10 15

Pro Asp Val Leu
 20

<210> 4
 <211> 20
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Designed
 peptide to act as an immunogen

<400> 4
 Ile Val Gly Gly Tyr Thr Cys Ser Arg Asn Ser Val Pro Tyr Gln Val
 1 5 10 15

Ser Leu Asn Ser
 20

<210> 5
 <211> 20
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Designed
 peptide to act as an immunogen

<400> 5
 Leu Gln Gly Val Val Ser Trp Gly Ala Gly Cys Ala Gln Lys Gly Lys
 1 5 10 15

Pro Gly Val Ser
 20